Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:ALNY NASDAQ:INCY NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$232.02+0.6%$214.12$163.81▼$244.81$409.55B0.516.48 million shs3.03 million shsALNYAlnylam Pharmaceuticals$456.61-0.1%$450.21$205.87▼$484.21$59.85B0.36978,535 shs444,313 shsINCYIncyte$83.63-1.3%$84.16$53.56▼$88.66$16.33B0.731.84 million shs620,334 shsREGNRegeneron Pharmaceuticals$558.04-2.1%$573.83$476.49▼$1,024.36$59.28B0.311.10 million shs715,406 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.10%-2.51%+9.77%+20.13%+18.68%ALNYAlnylam Pharmaceuticals+1.39%-0.88%-5.22%+45.09%+68.68%INCYIncyte-0.74%-1.77%-0.99%+23.56%+28.88%REGNRegeneron Pharmaceuticals+1.07%-5.02%+2.40%+0.38%-43.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$232.02+0.6%$214.12$163.81▼$244.81$409.55B0.516.48 million shs3.03 million shsALNYAlnylam Pharmaceuticals$456.61-0.1%$450.21$205.87▼$484.21$59.85B0.36978,535 shs444,313 shsINCYIncyte$83.63-1.3%$84.16$53.56▼$88.66$16.33B0.731.84 million shs620,334 shsREGNRegeneron Pharmaceuticals$558.04-2.1%$573.83$476.49▼$1,024.36$59.28B0.311.10 million shs715,406 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.10%-2.51%+9.77%+20.13%+18.68%ALNYAlnylam Pharmaceuticals+1.39%-0.88%-5.22%+45.09%+68.68%INCYIncyte-0.74%-1.77%-0.99%+23.56%+28.88%REGNRegeneron Pharmaceuticals+1.07%-5.02%+2.40%+0.38%-43.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.79Moderate Buy$231.90-0.05% DownsideALNYAlnylam Pharmaceuticals 2.79Moderate Buy$448.04-1.88% DownsideINCYIncyte 2.22Hold$84.791.38% UpsideREGNRegeneron Pharmaceuticals 2.79Moderate Buy$817.4646.49% UpsideCurrent Analyst Ratings BreakdownLatest INCY, ABBV, REGN, and ALNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$231.00 ➝ $284.0010/10/2025ALNYAlnylam PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$570.0010/10/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$761.00 ➝ $756.0010/9/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$250.0010/9/2025INCYIncyteJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$73.00 ➝ $89.0010/8/2025INCYIncyteOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform10/8/2025ABBVAbbVieWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025ALNYAlnylam PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025INCYIncyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025REGNRegeneron PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/6/2025ALNYAlnylam PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$405.00 ➝ $475.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B7.28$14.98 per share15.49$1.90 per share122.11ALNYAlnylam Pharmaceuticals$2.46B24.31N/AN/A$0.52 per share878.10INCYIncyte$4.58B3.56$0.54 per share154.23$17.90 per share4.67REGNRegeneron Pharmaceuticals$14.20B4.16$45.22 per share12.34$268.50 per share2.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10110.4016.601.356.45%699.66%13.64%10/31/2025 (Estimated)ALNYAlnylam Pharmaceuticals-$278.16M-$2.47N/A513.04N/A-12.96%-273.52%-7.39%10/30/2025 (Estimated)INCYIncyte$32.62M$4.4019.0112.790.6718.99%21.99%14.43%11/4/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.6814.0914.681.8131.37%15.06%11.77%10/28/2025 (Estimated)Latest INCY, ABBV, REGN, and ALNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025INCYIncyte$1.65N/AN/AN/AN/AN/A10/31/2025Q3 2025ABBVAbbVie$3.26N/AN/AN/A$15.58 billionN/A10/30/2025Q3 2025ALNYAlnylam Pharmaceuticals$1.39N/AN/AN/A$943.37 millionN/A10/28/2025Q3 2025REGNRegeneron Pharmaceuticals$9.73N/AN/AN/A$3.57 billionN/A8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.43$12.89+$4.46$12.81$3.30 billion$3.68 billion7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion7/31/2025Q2 2025ALNYAlnylam Pharmaceuticals-$0.54$0.32+$0.86-$0.51$633.54 million$773.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.562.83%N/A312.38%53 YearsALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.63%N/A8.87%N/ALatest INCY, ABBV, REGN, and ALNY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/5/2025ABBVAbbViequarterly$1.643.08%10/15/202510/15/202511/14/20258/1/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%8/18/20258/18/20259/3/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61ALNYAlnylam Pharmaceuticals4.102.802.75INCYIncyte0.012.852.78REGNRegeneron Pharmaceuticals0.094.603.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ALNYAlnylam Pharmaceuticals92.97%INCYIncyte96.97%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%ALNYAlnylam Pharmaceuticals1.50%INCYIncyte17.80%REGNRegeneron Pharmaceuticals7.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableALNYAlnylam Pharmaceuticals2,230131.08 million129.11 millionOptionableINCYIncyte2,617195.28 million160.52 millionOptionableREGNRegeneron Pharmaceuticals15,106105.99 million98.55 millionOptionableINCY, ABBV, REGN, and ALNY HeadlinesRecent News About These CompaniesRegeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments2 hours ago | tipranks.comRegeneron Completes Study on Aflibercept’s Safety in Real-World Settings2 hours ago | tipranks.comWhat If You Were Missing The Value In Regeneron Pharmaceuticals Stock?October 10 at 9:08 AM | forbes.comWeiss Ratings Reaffirms Hold (C-) Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)October 10 at 5:38 AM | marketbeat.comLeo Wealth LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGNOctober 10 at 5:04 AM | marketbeat.comAlnylam and Regeneron Join Forces in Promising Alzheimer’s StudyOctober 9 at 12:31 PM | tipranks.comNew FDA approval for LibtayoOctober 9 at 12:07 PM | thepharmaletter.comTRegeneron Gets FDA Nod for Label Expansion of Oncology Drug LibtayoOctober 9 at 10:15 AM | zacks.com8,976 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Bar Harbor Wealth ManagementOctober 9 at 4:47 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by QRG Capital Management Inc.October 9 at 3:32 AM | marketbeat.comUS FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancerOctober 8 at 4:31 PM | reuters.comLibtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of ...October 8 at 4:02 PM | markets.businessinsider.comRegeneron stock rises after FDA approves Libtayo for high-risk skin cancerOctober 8 at 4:02 PM | za.investing.comLibtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and RadiationOctober 8 at 2:31 PM | globenewswire.comDohj LLC Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGNOctober 8 at 7:16 AM | marketbeat.comKLP Kapitalforvaltning AS Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGNOctober 8 at 4:43 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Valeo Financial Advisors LLCOctober 8 at 4:25 AM | marketbeat.comRegeneron (REGN): Reevaluating Valuation Following Breakthrough Trial Results and Evkeeza’s FDA Pediatric ApprovalOctober 7 at 5:21 PM | finance.yahoo.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Slow Capital Inc.October 7 at 6:59 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Ameliora Wealth Management Ltd.October 7 at 6:02 AM | marketbeat.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarOctober 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Exceptional Stocks to Build Long-Term WealthBy Chris Markoch | October 6, 2025Why AbbVie and Johnson & Johnson Could Outperform PfizerBy Chris Markoch | October 8, 2025INCY, ABBV, REGN, and ALNY Company DescriptionsAbbVie NYSE:ABBV$232.05 +1.36 (+0.59%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Alnylam Pharmaceuticals NASDAQ:ALNY$456.83 -0.12 (-0.03%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Incyte NASDAQ:INCY$83.63 -1.12 (-1.32%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Regeneron Pharmaceuticals NASDAQ:REGN$558.00 -11.90 (-2.09%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
